Viridian Therapeutics, Inc.
VRDN
$12.38
-$0.43-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 72.00K | 72.00K | 86.00K | 72.00K | 72.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.00K | 72.00K | 86.00K | 72.00K | 72.00K |
| Cost of Revenue | 5.75M | 238.25M | -- | 5.79M | 6.68M |
| Gross Profit | -5.68M | -238.18M | 86.00K | -5.72M | -6.61M |
| SG&A Expenses | 17.10M | 15.58M | 14.41M | 16.07M | 15.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.94M | 87.54M | 83.57M | 72.26M | 55.97M |
| Operating Income | -93.87M | -87.47M | -83.48M | -72.19M | -55.90M |
| Income Before Tax | -86.91M | -79.73M | -76.69M | -64.99M | -48.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.91M | -79.73M | -76.69M | -64.99M | -48.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.91M | -79.73M | -76.69M | -64.99M | -48.54M |
| EBIT | -93.87M | -87.47M | -83.48M | -72.19M | -55.90M |
| EBITDA | -93.75M | -87.35M | -83.35M | -72.05M | -55.75M |
| EPS Basic | -0.87 | -0.23 | -1.15 | -1.02 | -0.59 |
| Normalized Basic EPS | -0.67 | -0.62 | -0.72 | -0.64 | -0.50 |
| EPS Diluted | -0.87 | -0.23 | -1.15 | -1.02 | -0.59 |
| Normalized Diluted EPS | -0.67 | -0.62 | -0.72 | -0.64 | -0.50 |
| Average Basic Shares Outstanding | 81.34M | 80.05M | 66.42M | 63.85M | 61.10M |
| Average Diluted Shares Outstanding | 81.34M | 80.05M | 66.42M | 63.85M | 61.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |